Compare · GENB vs NVO
GENB vs NVO
Side-by-side comparison of Generate Biomedicines Inc. (GENB) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GENB and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $220.35B.
- NVO has been more active in the news (5 items in the past 4 weeks vs 1 for GENB).
- NVO has more recent analyst coverage (25 ratings vs 6 for GENB).
- Company
- Generate Biomedicines Inc.
- Novo Nordisk A/S
- Price
- $12.80-0.47%
- $41.18+6.93%
- Market cap
- -
- $220.35B
- 1M return
- +7.74%
- -
- 1Y return
- -0.35%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 1
- 5
- Recent ratings
- 6
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GENB
- H.C. Wainwright initiated coverage on Generate Biomedicines with a new price target
- Piper Sandler initiated coverage on Generate Biomedicines with a new price target
- Morgan Stanley initiated coverage on Generate Biomedicines with a new price target
- Cantor Fitzgerald initiated coverage on Generate Biomedicines
- Guggenheim initiated coverage on Generate Biomedicines with a new price target
- Goldman initiated coverage on Generate Biomedicines with a new price target
- New insider Pioneering Medicines 02, Llc claimed ownership of 1,562,500 shares (SEC Form 3)
- Chief Executive Officer Nally Michael bought $240,000 worth of shares (20,000 units at $12.00), increasing direct ownership by 4% to 572,707 units (SEC Form 4)
- SEC Form 4 filed by Director Vessey Rupert
- Chief People Officer Grous Beth bought $4,800 worth of shares (300 units at $16.00) (SEC Form 4)
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S